Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Transcatheter chemoembolisation proves popular liver cancer treatment

Millennium Research Group : 14 March, 2008  (Company News)
More than 85 percent of liver cancer treatments performed in IR suites during 2007 used transcatheter chemoembolisation according to data released by Millennium Research Group's (MRG's) US Interventional Radiology (IR) Marketrack.
Transcatheter chemoembolisation is a procedure that delivers chemotherapy agents directly to a tumour through minimally invasive means.

Microsphere particles, including Boston Scientific's Contour SE, Biosphere Medical's Embosphere, and others, were used in 40 percent of these treatments. Overall, chemoembolisation particles generated nearly 20 percent of total microsphere revenue.

Chemoembolisation procedures are a key segment in the overall embolic particle market, which, in addition to standard microspheres, includes drug-infused microspheres, selective internal radiation therapy (SIRT) spheres, and polyvinyl alcohol (PVA) particles. MRG's US IR Marketrack service monitors the adoption of embolic particles for liver cancer, uterine fibroids, aneurysms, haemorrhages, and vascular anomalies.

'In chemoembolisation, chemotherapy agents are mixed with embolic particles and are delivered through a Catheter directly to the tumour, thereby localising the chemo treatment' said Phil Scrutton, Analyst at MRG. 'The particles also embolise the surrounding arteries, blocking blood flow to the cancerous tissue. This slows diffusion of the chemotherapy agents away from the tumour, which increases its effectiveness in targeting the liver tumour, while the embolisation also deprives the tumour of oxygen and nutrients.'

Liver cancer has historically had a poor prognosis, but the use of embolic particles in conjunction with drugs in chemoembolisation, while not a cure, is leading to longer life expectancies for cancer sufferers. These positive clinical outcomes, the availability of improved embolisation technologies, and an increasing rate of patient referrals for this treatment are all contributing to embolic particle market growth.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo